Multicenter, Prospective Phase-I/II-study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity
after each cycle
Yes
Jalid Sehouli
Principal Investigator
Charité Campus Virchow Klinikum
Germany: Federal Institute for Drugs and Medical Devices
310300
NCT00170625
June 2004
September 2010
Name | Location |
---|